METHODS OF ISOLATING NON-SENESCENT CARDIAC STEM CELLS AND USES THEREOF
The invention describes the isolation and methods of use of a non-senescent pool of adult cardiac stem cells. Methods for repairing aged myocardium or damaged myocardium using the isolated non-senescent adult cardiac stem cells are also disclosed. In addition, the invention describes a method for preventing or treating heart failure.
1 . A method for selecting non-senescent adult cardiac stem cells comprising:
(a) extracting cardiac stem cells from a subject;
(b) expanding and culturing said stem cells;
(c) determining at least one characteristic of said cultured stem cells, wherein said characteristic is selected from the group consisting of telomere length, telomerase activity, and IGF-1 receptor expression; and
(d) selecting said stem cells with long telomeres, stem cells with at least 60% telomerase activity as compared to a control, stem cells expressing IGF-1 receptor, or combinations thereof, wherein said selected stem cells are non-senescent adult cardiac stem cells.
2 . The method of claim 1 , wherein said extracting cardiac stem cells from a subject comprises obtaining a myocardial tissue specimen from the subject; and isolating said stem cells from said tissue specimen.
3 . The method of claim 1 , wherein said stem cells express at least one stem cell marker selected from the group consisting of c-kit, MDR1, and combinations thereof.
4 . The method of claim 1 , wherein said subject is human.
5 . The method of claim 4 , wherein said stem cells with telomeres at least 5 kbp in length are selected.
6 . The method of claim 1 , wherein said stem cells expressing IGF-1 receptor are selected.
7 . A method for repairing damaged myocardium and/or age-related cardiomyopathy in a subject in need thereof comprising:
administering non-senescent adult cardiac stem cells to an area of damaged and/or aged myocardium, wherein the non-senescent adult cardiac stem cells are selected by the method of claim 1 , and wherein the cardiac stem cells generate myocardium and/or myocardial cells after their administration, thereby repairing damaged myocardium and/or age-related cardiomyopathy.
8 . The method of claim 7 , wherein the non-senescent adult cardiac stem cells are activated prior to administration.
9 . The method of claim 8 , wherein said stem cells are activated by exposing the stem cells to one or more cytokines.
10 . The method of claim 9 , wherein said one or more cytokines are insulin-like growth factor-1, hepatocyte growth factor, or a variant thereof.
11 . The method of claim 7 , wherein said administered non-senescent cardiac stem cells are autologous.
12 . The method of claim 7 , wherein said non-senescent cardiac stem cells are administered by an intracoronary route of administration.
13 . A method of preventing or treating heart failure in a subject comprising:
administering non-senescent cardiac stem cells to the subject's heart, wherein the non-senescent cardiac stem cells are selected by the method of claim 1 ; and
administering an angiotensin II receptor antagonist.
14 . The method of claim 13 , wherein said non-senescent adult cardiac stem cells are activated prior to administration.
15 . The method of claim 14 , wherein said stem cells are activated by exposing the stem cells to one or more cytokines.
16 . The method of claim 15 , wherein said one or more cytokines are insulin-like growth factor-1, hepatocyte growth factor, or a variant thereof.
17 . The method of claim 13 , wherein said angiotensin II receptor antagonist is selected from the group consisting of Valsartan, Telmisartan, Losartan, Irbesartan, Olmesartan, Candesartan, and Eprosartan.
18 . The method of claim 13 , further comprising the administration of an angiotensin converting enzyme (ACE) inhibitor.
19 . The method of claim 18 , wherein said ACE inhibitor is selected from the group consisting of Benazepril, Enalapril, Lisinopril, Captopril, Fosinopril, Ramipril, Perindopril, Quinapril, Moexipril, and Trandolapril.
20 . The method of claim 18 , wherein said angiotensin II receptor antagonist and said ACE inhibitor are administered in multiple doses over a period of time subsequent to the administration of said non-senescent cardiac stem cells.
21 . The method of claim 13 , wherein said non-senescent cardiac stem cells are administered by an intracoronary route of administration.
22 . A pharmaceutical composition comprising isolated human cardiac stem cells and a pharmaceutically acceptable carrier, wherein said isolated human cardiac stem cells are c-kit positive, IGF-1 receptor positive, and have telomeres greater than 5 kbp in length.